Latest News
Alumis Inc.
- Alumis Inc. (ALMS) Slips 3.01% to $6.12 as Shares Press Toward Lower Support - Bear Pennant
- Alumis posts new Phase III psoriasis data as oral TYK2 race heats up
- Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
- Alumis reports strong Phase 3 data for envudeuc...
- Alumis Reports Positive Phase 3 ONWARD Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis, Advances Toward 2026 NDA Filing
- Alumis presents new psoriasis drug data, plans late 2026 filing
- H.C. Wainwright reiterates Alumis stock rating on TYK2 data
Headlines from the last 30 days, linking to the original publishers. See all market news →